Cadrenal to Seek Rare Pediatric Designation for Tecarfarin, Eyeing $180–205M Voucher
CVKD•Cadrenal Therapeutics plans to submit Rare Pediatric Disease Designation to FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms requiring chronic anticoagulation. If approved, Cadrenal would be eligible for a Priority Review Voucher worth $180–205 million and highlight its Phase-3-ready CAD-1005 12-LOX platform at BIO International.
1. RPDD Submission for Tecarfarin
Cadrenal Therapeutics plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for its oral anticoagulant tecarfarin to treat pediatric Kawasaki disease patients who develop coronary artery aneurysms and require chronic anticoagulation therapy.
2. Priority Review Voucher Impact
If the FDA grants RPDD and approves tecarfarin, Cadrenal would qualify for a Priority Review Voucher valued between $180 million and $205 million, which can be used to expedite review of another drug or sold to generate substantial non-dilutive capital.
3. Pipeline Presentation at BIO 2026
At the 2026 BIO International Convention, Cadrenal will present its Phase-3-ready CAD-1005 12-LOX inhibitor, targeting Heparin-Induced Thrombocytopenia and Cardiac Surgery-Associated Acute Kidney Injury, alongside the tecarfarin pediatric program to attract global pharmaceutical partnerships.
